Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-yearStrong growth in key commercial metrics, including ...
VIVUS Launches QSYMIA® in the United Arab Emirates
VIVUS, in collaboration with PharmaAccess, its marketing partner in the Middle East North African (MENA) region, intends to provide healthcare providers with more treatment options to combat this ...
Morningstar5d
VIVUS Launches QSYMIA® in the United Arab Emirates
Common side effects of QSYMIA in adults include numbness or tingling in the hands, arms, feet, or face (paraesthesia), dizziness, changes in the way foods taste or loss of taste (dysgeusia ...
pharmaphorum6d
GSK bolsters respiratory pipeline with Bellus Health buy
It has pointed to a lower tendency to cause taste disturbances (dysgeusia) than other compounds in the class. In the phase 2b SOOTHE trial reported in 2021, camlipixant was shown to be effective ...
The Lancet2d
Monumen-TAL progress in the treatment of relapsed multiple myeloma
Despite meaningful improvements in overall health-related quality of life due to its robust efficacy, a small pilot study showed rapid development of objectively measured and patient-reported ...
Canadian Medical Association Journal5d
Outcomes for people experiencing homelessness with COVID-19 presenting to emergency departments in Canada, compared with housed patients
Background: Whether people experiencing homelessness (PEH) have different COVID-19 outcomes than housed patients in Canada remains unclear. We sought to ascertain whether rates of in-hospital ...
Frontiers6d
GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential
Alcohol is one of the most widely used substances. Alcohol use accounts for 5.1% of the global disease burden, contributes substantially to societal and economic costs, and leads to approximately 3 ...